


ACC: Empagliflozin cuts heart failure hospitalization risk after AMI

April 8 2024, by Elana Gotkine



For patients with acute myocardial infarction at risk for heart failure, empagliflozin reduces the risk for heart failure hospitalization, according to a study published online April 6 in *Circulation* to coincide with the annual meeting of the American College of Cardiology, held from April

6 to 8 in Atlanta.

Adrian Hernandez, M.D., from Duke University in Durham, North Carolina, and colleagues examined the impact of empagliflozin on first and recurrent [heart failure](#) events in patients after myocardial infarction in a double-blind, randomized trial. The study included 6,522 patients hospitalized for [acute myocardial infarction](#) at risk for heart failure based on newly developed left ventricular ejection fraction of

Citation: ACC: Empagliflozin cuts heart failure hospitalization risk after AMI (2024, April 8) retrieved 2 May 2024 from

<https://medicalxpress.com/news/2024-04-acc-empagliflozin-heart-failure-hospitalization.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.